Navigation Links
Echosens: Launch of the FibroScan®502 Touch
Date:10/27/2011

PARIS, October 27, 2011 /PRNewswire/ --

Since its initial inception, Echosens has a history of innovation and it continues to widen and strengthen its product range with the recent introduction of the FibroScan® 502 Touch.

Equipped with a new and more ergonomic tactile interface, and based on patented Vibration-Controlled Transient Elastography (VCTE™), the latest FibroScan® provides a reliable, accurate and reproducible assessment of liver tissue stiffness.

This patented VCTE technology, developed by Echosens, is unique in measuring liver stiffness at a pre-determined and controlled 50 Hz frequency.

The FibroScan® 502 Touch offers enhanced patient data management with more complete and personalized exam reports. Compatible with the complete range of FibroScan probes (S+, M+ and XL+) it offers simultaneous connection of 2 probes giving flexibility for the patient assessment.  An indicator recommends the probe best suited to the patient's morphology.

Echosens' FS 502 Touch represents a quicker and more complete device built around the latest generation of electronics.

Continuing Echosens' history of innovation, the FS 502 Touch is further enhanced by the optional integration of the latest technological innovation: CAP™ (Controlled Attenuation Parameter), the new parameter for steatosis assessment and quantification.

Echosens has also launched new software for managing FibroScan® examinations: the Desk Solution. This comprehensive and innovative solution provides ready access to FibroScan assessments on the physician's desk-top PC.

Echosens products are widely available in most global markets and the company is actively pursuing the necessary FDA approvals to homologate its devices for sale in the United States.

About Echosens and Fibroscan®

FibroScan® is designed to quantify hepatic elasticity and steatosis in a non-invasive manner in chronic liver diseases assessment.

Founded in 2001, Echosens supplies its products in more than 70 countries through a global network of suppliers. It dedicates a major portion of its activity to research and development in order to invent new medical devices and open up new medical perspectives.  The organization works in close cooperation with health professionals and patients' associations to facilitate management and therapeutic monitoring of patients.  To date, there around 400 publications which attest to the efficacy of FibroScan in clinical practice.

Press Contact

ECHOSENS
Richard GUILLAUME
contact@echosens.com
+33-144-827850

 


'/>"/>
SOURCE Echosens
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. nContact, Inc. Launches New Corporate Websites
2. First Response Launches IVF Fundraising Resource for Those Trying for a Baby
3. Latest Pharmaceutical Launch Strategies Demonstrate Growing Importance of Thought Leader Engagement at Market Entry
4. CDC Launches Effort to Protect Cancer Patients From Infections
5. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
6. Gamma Pharmaceuticals, Inc., Launches Retail Promotions for Gamma Energy Gel™ in New York City and Houston
7. Recent Research Provides Formula for Timely Product Launch: Good Science + Effective FDA Relations
8. Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology
9. Arthrosurface Launches Worlds First Talus Resurfacing Implant for the Ankle
10. Medical Alarm and Harrington Multi Media Schedule Production for MediPendant™ National Television Launch
11. DYMO® Labeling Launches High-Resolution Identification Scanner for Health Records Processing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology:
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... Summer ... rain storms wreak havoc across communities and often result in massive tree damage requiring ... actions homeowners can take now including tree trimming, tree cabling and hazardous tree removal. ...
(Date:7/24/2017)... Falls Church, VA (PRWEB) , ... July 24, ... ... is figuring out how to change manufacturers future. , The agency is hammering ... Century Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced Dermatology, ... Bellmore, New York, (516) 784-5858. The office opened earlier this summer and is ... Friedman and Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and medical ...
(Date:7/24/2017)... ... 24, 2017 , ... “Nana Nana Boo Boo”: a delightful tale of a ... “Nana Nana Boo Boo” is the creation of published author Michael Rush, a Deputy ... Faith Publishing, Michael Rush’s new book presents the importance of manners in a way ...
(Date:7/24/2017)... ... ... “Journey to the Light: The Quest for Happiness and Love. . . ... finding herself. “Journey to the Light: The Quest for Happiness and Love. . ... of newsletters, manuals, and articles, who has recently decided to expand her literary horizons ...
Breaking Medicine News(10 mins):